Healthcare Industry News: Roche
News Release - September 21, 2010
Jeffrey A. Winton Named Vice President of Communications at Eli Lilly and CompanyINDIANAPOLIS, Sept. 21 (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE:LLY ) today announced that pharmaceutical industry veteran Jeffrey A. Winton has been named vice president of communications. Winton will assume this role on October 11, and will become a member of the Eli Lilly and Company Global Corporate Affairs Leadership Team. He will report to Bart Peterson, senior vice president, corporate affairs and communications.
In this position, Winton will be responsible for communications across Lilly, including oversight of corporate and product communications, employee communications, issues management, and digital and social communications.
"Jeff brings unique biopharmaceutical experience that will help guide Lilly through one of the more challenging periods in our company's history. He has a clear vision for how Lilly can expand and enhance our communications with an increasingly global audience," said Peterson.
Winton most recently served as co-owner and managing partner of West Mill Consulting in Long Valley, New Jersey, which specializes in strategic global communications and public relations, marketing research and executive placement work. In this capacity, he also served as interim head, communications and public relations for Bayer Healthcare Pharmaceuticals following the merger of Bayer and Schering AG (Berlex).
Prior to forming West Mill, Winton served in various senior leadership and communications roles with Schering-Plough Corporation, Pharmacia, Hoffmann-La Roche and American Cyanamid Company. He also worked for leading communications agencies in New York and the Midwest.
Winton graduated from Cornell University, where he holds a Bachelor of Science degree with distinction, and he has also completed graduate level course work at Union Theological Seminary, New York.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.
Source: Eli Lilly
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsFDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19